These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23887301)

  • 21. High mitochondria content is associated with prostate cancer disease progression.
    Grupp K; Jedrzejewska K; Tsourlakis MC; Koop C; Wilczak W; Adam M; Quaas A; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Schlomm T; Minner S; Steurer S
    Mol Cancer; 2013 Nov; 12(1):145. PubMed ID: 24261794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.
    Schroeder C; Grell J; Hube-Magg C; Kluth M; Lang D; Simon R; Höflmayer D; Minner S; Burandt E; Clauditz TS; Büscheck F; Jacobsen F; Huland H; Graefen M; Schlomm T; Sauter G; Steurer S
    BMC Cancer; 2019 Mar; 19(1):193. PubMed ID: 30823906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
    Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
    Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
    Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
    BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer.
    Burdelski C; Strauss C; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Krech T; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S
    Oncotarget; 2015 Apr; 6(10):8377-87. PubMed ID: 25762627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
    Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
    Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
    Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.
    Melling N; Taskin B; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Heinzer H; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Schlomm T; Krech T
    Prostate; 2016 Feb; 76(3):259-72. PubMed ID: 26764246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
    Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
    Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
    Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer.
    Marx A; Koopmann L; Höflmayer D; Büscheck F; Hube-Magg C; Steurer S; Eichenauer T; Clauditz TS; Wilczak W; Simon R; Sauter G; Izbicki JR; Huland H; Heinzer H; Graefen M; Haese A; Schlomm T; Bernreuther C; Lebok P; Bonk S
    Cancer Biol Med; 2021 Feb; 18(1):245-255. PubMed ID: 33628598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers.
    Burdelski C; Fitzner M; Hube-Magg C; Kluth M; Heumann A; Simon R; Krech T; Clauditz T; Büscheck F; Steurer S; Wittmer C; Hinsch A; Luebke AM; Jacobsen F; Minner S; Tsourlakis MC; Beyer B; Steuber T; Thederan I; Sauter G; Izbicki J; Schlomm T; Wilczak W
    Neoplasia; 2017 Apr; 19(4):279-287. PubMed ID: 28282546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
    Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
    Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
    Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
    Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
    Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
    Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.
    Eichenauer T; Federlein F; Möller K; Chirico V; Kind S; Lennartz M; Lutz F; Hube-Magg C; Höflmayer D; Fisch M; Huland H; Heinzer H; Graefen M; Haese A; Schroeder C; Lebok P; Minner S; Simon R; Sauter G; Schlomm T; Wilczak W; Steurer S; Luebke AM
    Pathology; 2020 Jun; 52(4):421-430. PubMed ID: 32317175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
    Hoogland AM; Jenster G; van Weerden WM; Trapman J; van der Kwast T; Roobol MJ; Schröder FH; Wildhagen MF; van Leenders GJ
    Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.